- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.12. | Intensity Therapeutics receives 180-day Nasdaq extension to regain compliance | 8 | Seeking Alpha | ||
| 05.12. | Intensity Therapeutics gets 180-day extension to meet Nasdaq price rule | 1 | Investing.com | ||
| 04.12. | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 07.11. | Intensity Therapeutics GAAP EPS of -$0.06 in-line | 8 | Seeking Alpha | ||
| INTENSITY THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 06.11. | Intensity Therapeutics Inc.: Intensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | 101 | PR Newswire | The Company expects to file a protocol amendment in the INVINCIBLE-4 Study to revise the dosing regimen for the INT230-6 treatment cohort, and to reinitiate... ► Artikel lesen | |
| 06.11. | INTENSITY THERAPEUTICS, INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 31.10. | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 3 | SEC Filings | ||
| 31.10. | Intensity Therapeutics announces pricing of $4M registered direct offering of common stock | 11 | Seeking Alpha | ||
| 31.10. | Kapitalerhöhung mit hohem Abschlag: Aktie von Intensity Therapeutics stürzt ab | 16 | Investing.com Deutsch | ||
| 31.10. | Intensity Therapeutics stock tumbles after pricing $4 million offering | 3 | Investing.com | ||
| 31.10. | Intensity Therapeutics sichert sich 4 Millionen US-Dollar durch registrierte Direktplatzierung | 11 | Investing.com Deutsch | ||
| 31.10. | Intensity Therapeutics prices $4 million registered direct offering | 1 | Investing.com | ||
| 31.10. | Intensity Therapeutics Stock Cools After-Hours Following 395% Surge: What You Should Know | 14 | Benzinga.com | ||
| 30.10. | Intensity Therapeutics stock soars after phase 1/2 data publication | 10 | Investing.com | ||
| 30.10. | Intensity Therapeutics publishes cancer treatment study results in Lancet journal | 27 | Investing.com | ||
| 23.10. | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 11 | SEC Filings | ||
| 10.09. | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 3 | SEC Filings | ||
| 10.09. | Intensity Therapeutics Inc.: Intensity Therapeutics Reports INVINCIBLE-4, Presurgical Triple-Negative Breast Cancer Study Update | 393 | PR Newswire | A pathological complete response ("pCR") has been observed in the first patient evaluated in Cohort A, where each patient receives two doses of INT230-6 eight days apart, followed... ► Artikel lesen | |
| 20.08. | Benchmark lowers Intensity Therapeutics stock price target to $1.50 on dilution | 10 | Investing.com | ||
| 12.08. | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 1 | SEC Filings |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 79,00 | +1,28 % | Alarm bei Evotec! BioNTech und Vidac Pharma mit Erfolgen beim Kampf gegen Krebs! Analysten raten zum Kauf! | Bei Evotec läuten die Alarmglocken. Ein Großaktionär ist komplett beim deutschen Biotech-Unternehmen ausgestiegen. Dabei notiert das Wertpapier auf dem Niveau von 2016. Einen Meilenstein hat dagegen... ► Artikel lesen | |
| NOVAVAX | 5,708 | +0,09 % | Novavax, Inc.: Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights | Total revenue of $70 million in the third quarter of 2025
Continued successful execution of Sanofi partnership with $225 million in milestones achieved year-to-date... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 47,600 | +1,71 % | Is CRISPR Therapeutics a Buy, Sell, or Hold in 2026? | ||
| EDITAS MEDICINE | 2,034 | +1,24 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| GINKGO BIOWORKS | 7,000 | -0,71 % | Ginkgo Bioworks and Agricen Enter Collaboration to Optimize Manufacturing Processes for a Key Agricultural Soil Amendment | Collaboration reduces time in fermenting complex bacterial strains, enabling continued focus on next-gen biological crop solutions.
BOSTON and PLANO, Texas, Dec.... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 2,175 | +3,82 % | Iovance Biotherapeutics, Inc.: Iovance Biotherapeutics Reports Potential Best-in-Class Clinical Data for Lifileucel TIL Cell Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC) | 26% Objective Response Rate Median Duration of Response Not Reached after 25 Months Follow Up Lifileucel Launch in Previously Treated Advanced NSCLC Expected in Second Half of 2027 SAN CARLOS, Calif.... ► Artikel lesen | |
| NOVOCURE | 10,810 | +0,89 % | Novocure CEO Ashley Cordova Resigns; Frank Leonard Named Replacement | WASHINGTON (dpa-AFX) - NovoCure Ltd. (NVCR), a Swiss medical devices and healthcare company, Monday announced that its chief executive officer, Ashley Cordova has resigned from the company.Frank... ► Artikel lesen | |
| ADAPTIMMUNE THERAPEUTICS | 0,029 | 0,00 % | Adaptimmune Therapeutics PLC: Adaptimmune Announces Changes to Board and Executive Leadership Team | Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 17, 2025) - Adaptimmune Therapeutics plc (OTC Pink: ADAPY) ("Adaptimmune" or the "Company") today announced changes... ► Artikel lesen | |
| SPERO THERAPEUTICS | 1,952 | -0,81 % | Spero Therapeutics, Inc.: Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis | CAMBRIDGE, Mass., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare... ► Artikel lesen | |
| X4 PHARMACEUTICALS | 2,450 | -100,00 % | X4 Pharmaceuticals: Milliardenversprechen Mavorixafor | Die Aktie von X4 Pharmaceuticals gewinnt an Bedeutung, da das Unternehmen seinen einzigen Wirkstoff Mavorixafor Schritt für Schritt in neue Märkte bringt und klinisch weiterentwickelt. Mit wichtigen... ► Artikel lesen | |
| GENERATION BIO | 5,530 | +1,47 % | XOMA Royalty Corporation Enters into Agreement to Acquire Generation Bio Co. | - Acquisition provides XOMA Royalty with potential milestone and royalty payments under Generation Bio's collaboration with Moderna - - Generation Bio's cell-targeted lipid nanoparticles (ctLNP) delivery... ► Artikel lesen | |
| NEUMORA THERAPEUTICS | 1,760 | +2,62 % | TECX, GKOS, GH, ALGN, NMRA Surge After Hours On Clinical Data And Earnings | WASHINGTON (dpa-AFX) - Several healthcare and life sciences names posted notable gains in after-hours trading, driven by clinical updates, earnings releases, and in some cases, unexplained momentum.Tectonic... ► Artikel lesen | |
| QIAGEN | 38,740 | +0,77 % | QIAGEN N.V.: QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $500 Million | Return of approximately $500 million maximum approved by shareholders set to be completed on January 7, 2026 Capital return to be conducted through synthetic share repurchase combines a... ► Artikel lesen | |
| DISC MEDICINE | 80,04 | -11,50 % | Disc Medicine Inc: Disc Medicine Reports Third Quarter 2025 Financial Results and Provides Business Update | Submitted a New Drug Application (NDA) for accelerated approval of bitopertin in erythropoietic protoporphyria (EPP) on September 29, 2025; Awarded the FDA Commissioner's National Priority Voucher... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,32 | +0,26 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen |
INTENSITY THERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +1,60 % bei einem Aktienkurs von 0,424 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INTENSITY THERAPEUTICS INC finden Sie auf Wallstreet Online.